2. Signaling Pathways
  3. Apoptosis
  4. Bcl-2 Family
  5. Mcl-1 Isoform

Mcl-1

Mcl-1 (myeloid cell leukemia-1) is a critical anti-apoptotic member of the BCL-2 protein family that preserves mitochondrial integrity by restraining the pro-apoptotic effectors BAK and BAX and preventing mitochondrial outer membrane permeabilization (MOMP)[1][2]. Mechanistically, Mcl-1 contains a hydrophobic BH3-binding groove that sequesters pro-apoptotic proteins and suppresses stress-induced apoptosis, thereby maintaining cell survival under physiological and pathological conditions[1][3]. Within the intrinsic apoptotic pathway, BH3-only proteins including NOXA, BIM, PUMA, and BID antagonize anti-apoptotic BCL-2 family members, and NOXA displays notable selectivity toward Mcl-1, promoting apoptotic signaling through Mcl-1 neutralization and degradation[4][5][6]. In cancer models, Mcl-1 overexpression contributes to tumor progression, chemoresistance, and disease relapse, highlighting its role as a major survival factor in malignant cells[7][8]. Compared with related anti-apoptotic isoforms such as BCL-2 and BCL-xL, Mcl-1 exhibits distinct binding preferences and plays a particularly important role in restraining BAK-dependent apoptosis, indicating non-redundant functions within the BCL-2 family network[9][10]. For experimental applications, selective Mcl-1 inhibitors and BH3 mimetics, including MCL-1 SAHB and S63845, disrupt Mcl-1-BAK interactions and induce apoptosis in MCL-1-dependent cancer cells, providing valuable tools for mechanistic studies and therapeutic target validation[11][12].

References:

Mcl-1 Related Products (80):

Cat. No. Product Name Effect Purity
  • HY-50907
    ABT-737
    		Inhibitor 99.64%
    ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-xL and Bcl-w inhibitor with EC50s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research.
  • HY-100741
    S63845
    		Inhibitor 99.94%
    S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor with a Kd of 0.19 nM for human MCL1.
  • HY-19741
    A-1331852
    		Inhibitor 99.93%
    A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM.
  • HY-114855
    BT2
    		Inhibitor 99.81%
    BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC). BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM.
  • HY-101533
    AZD-5991
    		Inhibitor 99.79%
    AZD-5991 is a potent and selective Mcl-1 inhibitor with an IC50 of 0.7 nM in FRET assay and a Kd of 0.17 nM in surface plasmon resonance (SPR) assay.
  • HY-N16746
    Nordentatin
    		Inhibitor
    Nordentatin is a selective inhibitor targeting GSK-3 with anticancer activity. Nordentatin can inhibit the phosphorylation of GSK-3, downregulate the anti-apoptotic protein Mcl-1 and activate caspase-3 to induce apoptosis (apoptosis). Nordentatin also inhibits the expression of migration-related protein MMP-9 and exerts anti-proliferation and anti-migration activities. Nordentatin is used in research into cancers such as neuroblastoma.
  • HY-15867
    Meayamycin B
    		Modulator
    Meayamycin B ((+)-Meayamycin B) is a potent SF3B1 inhibitor. Meayamycin B upregulates the proapoptotic Mcl-1S and downregulates Mcl-1L at the pre-mRNA splicing level. Meayamycin B does not regulate the alternative splicing of Bcl-x. Meayamycin B and ABT-737 (HY-50907) synergistically causes Apoptosis. Meayamycin B exhibits anticancer activity against non-small cell lung cancer.
  • HY-N17676
    3-Tridecylphenol
    3-Tridecylphenol is a cardanol. 3-Tridecylphenol can be isolated from K. hookeriana. 3-Tridecylphenol shows Ki values of >23 μM and >33 μM in BclxL/Bak and Mcl-1/Bid displacement assays, respectively. 3-Tridecylphenol can be used in cancer research.
  • HY-112218
    MIK665
    		Inhibitor 99.11%
    MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 (MCL1) inhibitor. MIK665 has an IC50 of 1.81 nM for MCL1.
  • HY-10969
    Obatoclax Mesylate
    		Inhibitor 99.85%
    Obatoclax Mesylate (GX15-070 Mesylate), a BH3 mimetic, is a pan-BCL-2 family proteins inhibitor with a Ki of 220 nM for BCL-2. Obatoclax Mesylate induces autophagy-dependent cell death and targets cyclin D1 for proteasomal degradation. Obatoclax Mesylate has anti-cancer and broad-spectrum antiparasitic activity.
  • HY-N0087
    Gambogic Acid
    		Inhibitor 98.34%
    Gambogic Acid (Beta-Guttiferrin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferrin) inhibits Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1 with IC50s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM.
  • HY-18628
    UMI-77
    		Inhibitor 99.66%
    UMI-77 is a selective Mcl-1 inhibitor, which shows high binding affinity to Mcl-1 (IC50=0.31 μM). UMI-77 binds to the BH3 binding groove of Mcl-1 with Ki of 490 nM, showing selectivity over other members of anti-apoptotic Bcl-2 members.
  • HY-12468
    A-1210477
    		Inhibitor 99.86%
    A-1210477 is a potent and selective inhibitor of MCL-1 with a Ki of 0.45 nM. A-1210477 specifically binds MCL-1 and promotes apoptosis of cancer cells in an MCL-1-dependent manner.
  • HY-125876
    PROTAC Bcl2 degrader-1
    		Inhibitor 99.80%
    PROTAC Bcl2 degrader-1 (Compound C5) is a PROTAC based on Cereblon ligand, which potently and selectively induces the degradation of Bcl-2 (IC50, 4.94 μM; DC50, 3.0 μM) and Mcl-1 (IC50, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1 (Blue: CRBN ligand, Black: linker；Pink: Mcl-1/Bcl-2 inhibitor, Nap-1).
  • HY-125877
    PROTAC Mcl1 degrader-1
    		Inhibitor 98.13%
    PROTAC Mcl1 degrader-1 (compound C3), a proteolysis targeting chimera (PROTAC) based on Cereblon ligand, is a potently and selectively Mcl-1 (Bcl-2 family member) inhibitor with an IC50 of 0.78 μM. PROTAC Mcl1 degrader-1 inhibits Bcl-2 with an IC50 of 0.54 μM.
  • HY-101565
    Tapotoclax
    		Inhibitor 99.53%
    Tapotoclax (AMG-176) is a potent, selective and orally active MCL-1 inhibitor, with a Ki of 0.13 nM.
  • HY-129478
    TC11
    		Inhibitor 99.55%
    TC11 is a MCL1 degrader and Caspase-9 and CDK1 activator. TC11 functions as a phenylacetylamide derivative and is structurally related to immunomodulatory active molecules. TC11 induces degradation of MCL1 leading to apoptotic death during prolonged mitotic arrest.
  • HY-12020
    TW-37
    		Inhibitor 99.50%
    TW-37 is a potent Bcl-2 inhibitor with Ki values of 260, 290 and 1110 nM for Mcl-1, Bcl-2 and Bcl-xL, respectively.
  • HY-15464
    (R)-(-)-Gossypol
    		Inhibitor 99.37%
    (R)-(-)-Gossypol (AT-101) is the levorotatory isomer of a natural product Gossypol. AT-101 is determined to bind to Bcl-2, Mcl-1 and Bcl-xL proteins with Kis of 260±30 nM, 170±10 nM, and 480±40 nM, respectively.
  • HY-15191
    Sabutoclax
    		Inhibitor 99.80%
    Sabutoclax is a potent and effective Bcl-2 Family (Bcl-2, Bcl-XL, Mcl-1, Bfl-1) inhibitor with IC50s of 0.32 μM, 0.31 μM, 0.20 μM, and 0.62 μM, respectively. Sabutoclax increases Bax, Bim, PUMA and survivin expression.
Cat. No. Product Name / Synonyms Application Reactivity